|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Prostatic Hyperplasia | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Carcinoma in Situ | |||||
| Hyperplasia | |||||
| Prostatic Intraepithelial Neoplasia | |||||
| 3 | More general conditions related to this trial | ||||
| Carcinoma | |||||
| Genital Diseases, Male | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms, Glandular and Epithelial | |||||
| Pathologic Processes | |||||
| Prostatic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| Polyphenon E, 200 mg EGCG bid | |||||
| placebo | |||||
| 5 | Sponsors listed in this trial | ||||
| H. Lee Moffitt Cancer Center and Research Institute | |||||
| National Cancer Institute (NCI) | |||||